Actor Kate Walsh, known for her role in “Grey’s Anatomy,” is joining a campaign to raise awareness about early testing for multiple types of cancer. The campaign focuses on promoting a test that can detect various cancers early. Some medications often used in cancer treatment include Tamoxifen, Imatinib, and Pembrolizumab.

Blood test company Grail has teamed up with ‘Grey’s Anatomy’ actress Kate Walsh to encourage people from Generation X to get tested for cancer early. The campaign, called “Generation Possible,” promotes tests that can detect multiple types of cancer early on. While the campaign is unbranded, it links to information about Grail’s Galleri test, which is specifically designed for this purpose.

In a video for the campaign, Walsh shares her personal story of how her parents’ cancer diagnoses inspired her to focus on her health. She emphasizes the importance of early detection and encourages viewers at high risk for cancer to discuss testing options with their doctors. She mentions that her parents didn’t have access to such tests, but she’s thankful that they are available now.

Traditional cancer screenings usually focus on just five types: colon, breast, cervical, prostate, and lung cancer. However, Grail’s MCED tests aim to identify a wider range of cancers much earlier. The company highlights that about 70% of cancer deaths are due to types not covered by standard screenings. Early detection can significantly increase survival rates.

The campaign includes a quiz to help people determine if they should consider these blood tests, which are prescription-only and intended for those with a higher cancer risk. Age is a significant factor, with cancer rates 13 times higher in those aged 50 and older compared to younger groups.

Josh Ofman, president of Grail, mentioned that many older Americans are interested in learning about these tests once they understand the benefits. Grail is focusing its efforts on the Galleri test, which checks for DNA markers from over 50 types of cancer. It is currently available in the U.S. as a lab-developed test, and Grail is working towards full FDA approval.

Scroll to Top